Hepatic arterial infusion chemotherapy of cisplatin and 5-Fluorouracil versus combined intraarterial 5-Fluorouracil and subcutaneous Interferon-alpha therapy in treating patients with unresectable liver cancer

Hepatic arterial infusion chemotherapy of cisplatin and 5-Fluorouracil versus combined intraarterial 5-Fluorouracil and subcutaneous Interferon-alpha therapy in treating patients with unresectable liver cancer - Hepatic arterial chemotherapy (FP versus IFN+5FU) for unresectable liver cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000012

Enrollment

100

Registered

2005-06-14

Start date

2004-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular carcinoma

Interventions

Hepatic arterial infusion chemotherapy of cisplatin and 5-Fluorouracil Continue the protocol as long as possible. combined intraarterial 5-Fluorouracil and subcutaneous Interferon-alpha therapy Cont

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Unresectable liver cancer involving inferior vena cava or main portal vein Child-Pugh A or B No previous chemotherapy Neutrophil count > 1000 /mL, Platelet count > 50000 / mL, Hemoglobin > 8 g/dl, Total bilirubin < 2 times the study center upper limit of normal (ULN), Creatine < the study center ULN, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 4 times the study center ULN Baseline performance status must be Eastern Cooperative Oncology Group (ECOG) 0, or 1.

Exclusion criteria

Exclusion criteria: High risk patient for esophageal varices rupture Malignant disease except hepatocellular carcinoma Allergy for 5FU, cisplatin, or interferron Severe heart disease psychiatric disorder Uncontrorable pleural effusion, ascites, or cardiac effusion

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Time to treatment failure Incidence of adverse events	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026